Targeting ERRα promotes cytotoxic effects against acute myeloid leukemia through suppressing mitochondrial oxidative phosphorylation

Acute myeloid leukemia (AML) is the most common type of leukemia with a 5-year survival of 24%. Sema4 researchers, in partnership with Chungnam National University College of Medicine, South Korea and the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, have discovered that an estrogen-related receptor (ERRα) plays an role in AML development. These findings present ERRα as a new therapeutic target for drug development with potential to improve treatment response for blood cancers.